10/534864

SEQUENCE LICETING 12 MAY 2005

		TA MAI	400
5	<110>	ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI	
	<120>	PTPRK IMMUNOGENIC PEPTIDES	
10	<130>	6423MEUR	
	<160>	20	
	<170>	PatentIn version 3.1	
15	<210>	1	
	<211>	16	
	<212>	PRT	
	<213>	Homo sapiens	
20	<400>	1	
	Pro Ty	r Tyr Phe Ala Ala Glu Leu Pro Pro Arg Asn Leu Pro Glu Pro	
-	1.	5 10 15	
		•	
25			
	<210>		
•	<211>	•	
	<212>.		
30	<213>	Homo sapiens	
30	<400>	2	
		tact ttgctgcaga actccccccg agaaacctac ctgagcct	4.0
	Cogcac	tact tryctycaga actoocoog agaaacotac otgagoot	48
35	<210>	3	
	<211>	24	
	<212>	DNA	
	<213>	synthetic oligonucleotide	
40			
	<400>	3	
	cgcgga	tccc gcatggtgtg tctg	24
45	-270-		
73	<210>	4	
	<211> <212>	27 DNA	
	<213>	synthetic oligonucleotide	
	72137	by mende te of i doubt feet fac	•
50	<400>	4	
		cctc agctcaggaa tcctgtt	27
			-,
	<210>	5	
55		44	
	<212>	DNA	
	<213>	synthetic oligonucleotide	
	4.5.5		
60	<400>	5	
60	gactag	ttct agatcgcgag cggccgccct tttttttttt tttt	44

WO 2004/043988 PCT/EP2003/012638 2 <210> 6 <211> 22 <212> DNA <213> synthetic oligonucleotide 5 <400> б 22 acctcgatta gttctcgagc tt <210> 7 10 <211> 24 <212> DNA <213> synthetic oligonucleotide 15 <400> 7 24 attaggacaa ggctggtggg cact <210> 8 <211> 20 <212> DNA 20 <213> synthetic oligonucleotide <400> 8 20 gtgctcctat cagtgcttat 25 <210> 9 <211> 18 <212> DNA <213> synthetic oligonucleotide 30 <400> 9 18 gcgtacgcac tgggtttt 35 <210> 10 <211> 27 <212> DNA <213> synthetic oligonucleotide 40 <400> 10 27 ctgcacccac accgaaccaa gagagaa 45 <210> 11 <211> 27 <212> DNA <213> synthetic oligonucleotide 50 <400> 11 cgcctggaaa tagatgttgt atccttt 27 <210> 12 55 <211> 21

21

<212> DNA

<400> 12

60

<213> synthetic oligonucleotide

ccgattgtca cccacagtga a

28

4

<210> 20
<211> 19
<212> DNA
5 <213> synthetic oligonucleotide
<400> 20

<400> 20 caccctctct ttcagccat 19